{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-128896","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.531131+00:00","generated_at":"2026-06-16T05:12:38.623174+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acrivon reports $159.5M cash as of March 31, 2023; runway into Q4 2024","bullets":["Cash and marketable securities totaled $159.5M as of March 31, 2023 (preliminary, unaudited).","Company confirms cash runway extends into at least the fourth quarter of 2024.","Preliminary estimate subject to change; actual results may differ materially.","Update provided in connection with virtual investor event on May 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-128896","json":"https://secwatch.observer/filing/0001193125-23-128896.json","markdown":"https://secwatch.observer/filing/0001193125-23-128896.md","text":"https://secwatch.observer/filing/0001193125-23-128896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/0001193125-23-128896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/d505148d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:12:38.623174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b720f8d906c37a45e5db57254cfd91171fb5d83","claim":"Acrivon Therapeutics, Inc. reported preliminary financial results for the three months ended March 31, 2023.","evidence_excerpt":"Acrivon Therapeutics, Inc. (the “Company”) will be updating its corporate presentation to include disclosure that the Company had $159.5 million of cash and marketable securities as of March 31, 2023 and to confirm its cash runway into at least the fourth quarter of 2024. Because the Company’s financial results for the three months ended March 31, 2023 have not been finalized or audited, the preliminary statement of the Company’s cash and marketable securities as of March 31, 2023 in this Item 2.02 is subject to change","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/0001193125-23-128896-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}